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Case Presentation

A 49 year-old African-American male presented to Thomas
Jefferson University Hospital in April of 2008 complaining of
generalized weakness and lightheadedness for 4 months. The
patient had a medical history of HIV/AIDS diagnosed in 2002
with a CD4 count of 0 cells/mm3 in 2005 and a history of noncompliance with highly active retroviral therapy (HAART). In
December of 2007 the patient was diagnosed with cryptococcal
meningitis and had a concomitant anemia with a hemoglobin
of 5.3 g/dL. At that time laboratory studies for parvovirus B19
(PB19) showed an IgG of 0.79 units and an IgM of 0.63 units
( a value less than 0.89 is considered negative). PB19 DNA by
PCR or direct DNA hybridization was not checked at that time.
A bone marrow biopsy was performed in January of 2008 to
determine the etiology of this severe hypoproliferative anemia,
revealing hypercellular marrow containing maturing trilineage
hematopoiesis with occasional non-caseating granulomas
with fungal elements. It was felt at this time that the anemia
was secondary to cryptococcal invasion of the bone marrow.
The patient was treated for cryptococcal meningitis with
fluorocytosine and liposomal amphotericin B for 2 weeks,
followed by oral fluconazole indefinitely, and was discharged
from the hospital.
When the patient presented in April of 2008, he was admitted
through the emergency department (ED) for a work-up of
symptomatic anemia. The patient was complaining of lightheadedness, generalized weakness, watery diarrhea, dry cough, and
shortness of breath. The patient denied fever, night sweats,
headache, blurry vision, joint pains, or rash. The patient denied
bloody or tarry stools, bleeding gums, easy bruising, or trauma.
On exam, the patient was afebrile and appeared disheveled and
cachectic with marked pallor. The patient had multiple small
cervical lymph nodes, no evidence of jugular venous distension,
and was clear to auscultation on lung exam. He had a regular
cardiac rhythm with no murmurs, a benign abdominal exam
with no hepatosplenomegaly, and no rashes, petechiae, or
peripheral edema.
The patient’s hemoglobin in the emergency room was 2.9 g/dL,
with a previous level of 13.1 g/dL one year prior to this admission.
The patient’s WBC count was 8.2 g/dL, with a differential of
24% neutrophils, 9% bands, 23% lymphocytes, 28% monocytes,
and 3% eosinophils, 3% metamyelocytes, and 9% myelocytes.
Laboratory values were as follows: mean corpuscular volume
was 87 fL (80-99 fL), lactate dehydrogenase 285 IU/L (100-200
IU/L), haptoglobin 331 mg/dL (16-200 mg/dL), urea-nitrogen
15 mg/dL, creatinine 1.7 mg/dL, aspartate aminotransferase 16
IU/L, alanine aminotransferase 11 IU/L, alkaline phosphatase
103 IU/L, albumin 3.6 g/dL, total bilirubin 0.3 mg/dL, and
direct bilirubin 0.0 mg/dL. CMV quantitative PCR was <100
copies/mL (<100copies/ml is negative). AFB stain from feces
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and blood cultures were negative. Stool studies were negative
for Entamoeba histolytica, Giardia lamblia, Cryptosporidium
species, Clostridium difficile and Shigella, Salmonella, and
Campylobacter species. The patient’s absolute reticulocyte
count was 3 cells/mm3 (20-76 cells/mm3), HIV viral load was
483,000 copies/mL and CD4 count was 7 cells/mm3. PB19 DNA
by PCR was positive, and there was a positive antibody response
with an IgG of 1.56 index units and IgM of 4.84 index units.
The patient received four units of packed red blood cells in
the ED and was subsequently started on intravenous immune
globulin (IVIG), to which he responded with a sustained
increase in his hemoglobin and no further requirements of
packed red blood cell transfusions. The patient’s acute renal
failure was felt to be secondary to pre-renal causes and improved
to a baseline value with fluid resuscitation. The patient was also
started on HAART with Atazanavir boosted with Ritonavir,
and Tenofovir-Emtricitabine. The patient’s hemoglobin on
discharge was 9.3 g/dL with an absolute reticulocyte count of
198 cells/mm3. On follow up, he continues to be non-compliant
with his HAART medications, but his repeat complete blood
count three months later in August 2008 revealed a hemoglobin
of 9.0 g/dL. Furthermore, the patient has not required a blood
transfusion since he completed IVIG treatment.

Discussion

Anemia is a common finding in HIV-infected patients. Several
causes of anemia have been described including medications
(e.g., antiretrovirals or trimethoprim-sulfamethoxazole),
neoplasms, opportunistic infections, and the immunological
effects of HIV itself. Although uncommon, PB19-related pure
red cell aplasia (PRCA) is an important diagnosis to consider in
this setting because it is a treatable cause of anemia.2,5 Human
PB19 infection is found worldwide in persons of all ages, with
the majority of adults having been exposed to the virus by age
50. The virus can be asymptomatic or can present in a variety of
ways including as erythema infectiosum, arthropathy, a papular
rash, pure red cell aplasia, hydrops fetalis in the neonate, and
other cardiac, rheumatologic, and neurological manifestations.2,
12
PB19 usually causes a benign, self-limited illness, but the virus
can present as a severe anemia in the immunocompromised
host.1,5
Figure 1. Characteristic giant
proerythroblasts in the bone
marrow are pathognomonic for
parvovirus B19 infection. The
diagnosis may be missed if the
biopsy is done within a few days
of a blood transfusion.

Case Reports

HIV-infected patients are particularly susceptible to infection
with PB19 and may be unable to produce an adequate antibody
response to the virus. This can result in a severe PRCA and a
prolonged anemia as the PB19 interrupts the production of
red blood cells in the bone marrow.5,6 These patients have been
shown to respond to a PB19 triggered PRCA with both IVIG
therapy as well as with highly active antiretroviral therapy.7,10 In
this case report, our patient presented with a profound anemia
caused by parvovirus B19 and responded well to treatment with
IVIG. The patient was also started on HAART, but was again
non-compliant with his medications.
A diagnosis of B19-PRCA should be considered in an afebrile,
HIV-infected patient with a normocytic anemia of relatively
recent onset, a virtual absence of blood reticulocytes, and a
normal renal function. Most reported cases are with a CD4 count
less than 100 cells/mm.7,12 The symptomatology is nonspecific,
and fever, skin rash, and arthropathy are characteristically
absent. Diagnosis of PB19-induced PRCA in an HIV-infected
patient is established when the following criteria are met: a bone
marrow aspirate consistent with PB19, a positive serum PB19
DNA by PCR or direct DNA hybridization, and no alternate
explanation for the red cell aplasia.7
It is important to note that the diagnosis may be missed in
immunocompromised patients because these patients may not be
able to formulate antibodies to the virus. Thereby, only checking
IgM and IgG antibodies to PB19 is not sufficient to exclude the
diagnosis, and either DNA by PCR or direct DNA hybridization
must be ordered.4 There are no clinical guidelines about the
treatment of HIV patients with PB19 infection; however, multiple
small studies have shown success with IVIG treatment with
good initial response. In patients with a CD4 count less than 80
cells/mm3, there is an unfortunately high relapse rate.8, 9 For this
reason, HAART has been described as a treatment strategy to
consider for PB19-induced PRCA, with some success reported in
small case studies.3,10 With substantive data lacking at this time,
adequate treatment for PB19 in HIV infected patients should be
determined in conjunction with an infectious diseases specialist
and should include close follow-up.
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